ES2060583T3 - NEW CEPHALOSPORINE DERIVATIVES, PROCEDURE FOR THEIR OBTAINING AND CORRESPONDING PHARMACEUTICAL PREPARATIONS. - Google Patents

NEW CEPHALOSPORINE DERIVATIVES, PROCEDURE FOR THEIR OBTAINING AND CORRESPONDING PHARMACEUTICAL PREPARATIONS.

Info

Publication number
ES2060583T3
ES2060583T3 ES87109613T ES87109613T ES2060583T3 ES 2060583 T3 ES2060583 T3 ES 2060583T3 ES 87109613 T ES87109613 T ES 87109613T ES 87109613 T ES87109613 T ES 87109613T ES 2060583 T3 ES2060583 T3 ES 2060583T3
Authority
ES
Spain
Prior art keywords
halogen
hydrogen
group
procedure
obtaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87109613T
Other languages
Spanish (es)
Inventor
Harry Allen Albrecht
Ka-Kong Chan
Dennis Dalton Keith
Rudolf Ludwig Then
Manfred Weigele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2060583T3 publication Critical patent/ES2060583T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/26—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVOS DERIVADOS DE CEFALOSPORINA DE FORMULA GENERAL (I) EN L A QUE M ES 0,1 O 2. R1 ES HIDROGENO O UN GRUPO ACILO, R2 ES HIDROGENO, ALCOXI INFERIOR, AMINO, ALQUILTIO INFERIOR O ALCANOILAMINO INFERIOR, R31 ES HIDROGENO, ALQUILO INFERIOR, ALQUENILO INFERIOR, C3-C7 CICLOALQUILO, ALQUILO INFERIOR-HALOGENO O HALOGENO-FENILO; Z R30-C O NITROGENO, R30 HIDROGENO O HALOGENO, O R31 Y R31 JUNTOS UN GRUPO C3-C5 ALQUILENO UN GRUPO MONOOXI C2-C4-ALQUILENO, UN GRUPO MONOOXI C2-C4-ALQUILENO O UN GRUPO DIOXI C1-C2-ALQUILENO, R32 ES HIDROGENO, HALOGENO, UN ALQUILO INFERIOR O UN ANILLO HETEROCICLICO CON 5 O 6 MIEMBROS SI ES CASO SUSTITUIDOS CON UNO, DOS O 3 ATOMOS DE OXIGENO, NITROGENO Y/O AZUFRE Y R33 ES HIDROGENO O HALOGENO Y R32 Y R33 JUNTOS CONSTITUYEN UN GRUPO DIOXI C1-C4-ALQUILENO. PROCEDIMIENTO PARA LA OBTENCION DE ESTOS COMPUESTOS Y PREPARADOS FARMACEUTICOS QUE LOS CONTIENEN CON ACTIVIDAD ANTIMICROBIANA.THE INVENTION IS RELATED TO NEW CEPHALOSPORIN DERIVATIVES OF GENERAL FORMULA (I) IN WHICH M IS 0.1 OR 2. R1 IS HYDROGEN OR AN ACIL GROUP, R2 IS HYDROGEN, LOWER ALCOXY, AMINO, LOWER ALKYLTYL, R31 IT IS HYDROGEN, LOWER ALKYL, LOWER ALKYNYL, C3-C7 CYCLLOALKYL, LOWER ALKYL-HALOGEN OR HALOGEN-PHENYL; Z R30-C OR NITROGEN, R30 HYDROGEN OR HALOGEN, OR R31 AND R31 TOGETHER A GROUP C3-C5 RENT A GROUP MONOOXI C2-C4-ALKYLENE, A GROUP MONOOXI C2-C4-ALKYLENE OR A GROUP C-DIO R32 IS HYDROGEN, HALOGEN, A LOWER ALKYL, OR A HETERO CYCLIC RING WITH 5 OR 6 MEMBERS IF SUBSTITUTED WITH ONE, TWO OR 3 ATOMS OF OXYGEN, NITROGEN, AND / OR SULFUR, AND R33 IS HYDROGEN OR HALOGEN AND HALOGEN. DIOXI C1-C4-ALQUILENO GROUP. PROCEDURE FOR OBTAINING THESE PHARMACEUTICAL COMPOUNDS AND PREPARATIONS THAT CONTAIN THEM WITH ANTIMICROBIAL ACTIVITY.

ES87109613T 1986-07-03 1987-07-03 NEW CEPHALOSPORINE DERIVATIVES, PROCEDURE FOR THEIR OBTAINING AND CORRESPONDING PHARMACEUTICAL PREPARATIONS. Expired - Lifetime ES2060583T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88155586A 1986-07-03 1986-07-03

Publications (1)

Publication Number Publication Date
ES2060583T3 true ES2060583T3 (en) 1994-12-01

Family

ID=25378717

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87109613T Expired - Lifetime ES2060583T3 (en) 1986-07-03 1987-07-03 NEW CEPHALOSPORINE DERIVATIVES, PROCEDURE FOR THEIR OBTAINING AND CORRESPONDING PHARMACEUTICAL PREPARATIONS.

Country Status (22)

Country Link
EP (1) EP0251330B1 (en)
JP (1) JPH0730083B2 (en)
KR (1) KR880001675A (en)
CN (1) CN1021226C (en)
AT (2) ATE97901T1 (en)
AU (1) AU603364B2 (en)
CS (2) CS270227B2 (en)
DE (1) DE3788306D1 (en)
DK (1) DK340387A (en)
ES (1) ES2060583T3 (en)
FI (1) FI88392C (en)
HU (1) HU200185B (en)
IE (1) IE61434B1 (en)
IL (1) IL83046A (en)
MC (1) MC1833A1 (en)
MX (1) MX7189A (en)
NO (1) NO168890C (en)
NZ (1) NZ220914A (en)
PH (1) PH23940A (en)
PT (1) PT85246B (en)
ZA (1) ZA874696B (en)
ZW (1) ZW12787A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227470A (en) * 1987-12-28 1991-06-25 Hoffmann La Roche Acyl derivatives of substituted cephem compounds; pharmaceutical compositions and methods for preparation and treatment
HUT49889A (en) * 1988-03-31 1989-11-28 Hoffmann La Roche Process for producing acyl derivatives
CA2001203C (en) * 1988-10-24 2001-02-13 Thomas P. Demuth, Jr. Novel antimicrobial dithiocarbamoyl quinolones
US5328908A (en) * 1988-10-24 1994-07-12 Procter & Gamble Pharmaceuticals, Inc. Antimicrobial quinolone thioureas
ES2148135T3 (en) * 1988-10-24 2000-10-16 Norwich Eaton Pharma NEW ANTIMICROBIAL ESTERS OF QUINOLONYL LACTAMS.
EP0366193A3 (en) * 1988-10-24 1992-01-08 Norwich Eaton Pharmaceuticals, Inc. Novel antimicrobial quinolonyl lactams
ES2129388T3 (en) * 1988-10-24 1999-06-16 Procter & Gamble Pharma FLUOROQUINOLONIL-CEFEMS ANTIMICROBIALS.
EP0366189A3 (en) * 1988-10-24 1992-01-02 Norwich Eaton Pharmaceuticals, Inc. Novel antimicrobial lactam-quinolones
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
GB8907617D0 (en) * 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
WO1991016327A1 (en) * 1990-04-18 1991-10-31 Norwich Eaton Pharmaceuticals, Inc. Antimicrobial quinolonyl lactams
US5066800A (en) * 1990-04-27 1991-11-19 Hoffmann-La Roche Inc. Qunoline intermediates useful therein for synthesizing antibacterial compounds
US5244892A (en) * 1990-10-16 1993-09-14 Kyorin Pharmaceutical Co., Ltd. Cephem compounds, and antibacterial agents
GB9216759D0 (en) * 1992-08-07 1992-09-23 Finpael Spa Process for the production of 7-amino thiazolyl cephalosporins
DE4234330A1 (en) * 1992-10-12 1994-04-14 Bayer Ag Quinolonecarboxylic acids
AU7706394A (en) * 1994-02-25 1995-09-11 Arrieta Munguia, Judith Marcia Quinolonylcarboxamidocephalosporin derivatives and pharmaceutical compositions containing them
MX9505113A (en) * 1995-12-07 1997-06-28 Aranda Lab Sa De Cv Cephalosporine-fluoroquinolonates derivatives and pharmaceutical compositions containing them.
CN113559105B (en) 2014-01-29 2026-06-23 维奥姆治疗有限公司 Treatment of resistant acne

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3971778A (en) 1972-05-12 1976-07-27 Glaxo Laboratories Limited Cephalosporins having (α-etherified oximino)acylamido groups at the 7-position
DE2362553A1 (en) * 1972-12-18 1974-06-20 Dainippon Pharmaceutical Co NEW PIPERAZINE DERIVATIVES
US4173199A (en) 1974-12-02 1979-11-06 Codama Holding S.A. Apparatus for reinforcing a fabric by applying a fluid reinforcing material thereto
DE2760123C2 (en) 1976-01-23 1986-04-30 Roussel-Uclaf, Paris 7-Aminothiazolyl-syn-oxyiminoacetamidocephalosporanic acids, their preparation and pharmaceutical compositions containing them
DE2716677C2 (en) 1977-04-15 1985-10-10 Hoechst Ag, 6230 Frankfurt Cephem derivatives and processes for their preparation
JPS5854157B2 (en) 1977-06-10 1983-12-02 山之内製薬株式会社 New derivatives of cephalosporin compounds and their production method
JPS5630964A (en) * 1979-08-22 1981-03-28 Kyorin Pharmaceut Co Ltd Novel substituted quinolinecarboxylic acid and its preparation
US4266049A (en) 1980-02-20 1981-05-05 Eli Lilly And Company Process for 3-iodomethyl cephalosporins
FR2501209B1 (en) * 1981-03-03 1986-07-04 Sanofi Sa NOVEL CEPHALOSPORIN DERIVATIVES AND ANTIBIOTIC DRUGS CONTAINING THE SAME
SE440354B (en) * 1981-02-19 1985-07-29 Kyorin Seiyaku Kk quinolinecarboxylic
FR2570702B1 (en) * 1984-09-27 1987-01-09 Sanofi Sa CEPHALOSPORIN DERIVATIVES, PROCESSES FOR OBTAINING THEM AND THEIR APPLICATION AS ANTIBIOTICS
DE3687279T2 (en) * 1985-01-21 1993-05-13 Nippon Pharma Dev Inst BETA LACTAM ANTIBIOTICS.
NZ227470A (en) * 1987-12-28 1991-06-25 Hoffmann La Roche Acyl derivatives of substituted cephem compounds; pharmaceutical compositions and methods for preparation and treatment

Also Published As

Publication number Publication date
IE61434B1 (en) 1994-11-02
FI88392B (en) 1993-01-29
ATE97901T1 (en) 1993-12-15
CN87105204A (en) 1988-06-29
EP0251330B1 (en) 1993-12-01
IL83046A0 (en) 1987-12-31
CN1021226C (en) 1993-06-16
HUT44258A (en) 1988-02-29
EP0251330A2 (en) 1988-01-07
NZ220914A (en) 1990-09-26
PT85246B (en) 1990-03-30
CS270227B2 (en) 1990-06-13
HU200185B (en) 1990-04-28
CS496787A2 (en) 1989-10-13
NO168890B (en) 1992-01-06
JPH0730083B2 (en) 1995-04-05
FI872951A0 (en) 1987-07-03
JPS6322586A (en) 1988-01-30
NO168890C (en) 1992-04-15
AU7500987A (en) 1988-01-07
NO872770L (en) 1988-01-04
IE871765L (en) 1988-01-03
PH23940A (en) 1990-01-23
IL83046A (en) 1992-07-15
DE3788306D1 (en) 1994-01-13
DK340387D0 (en) 1987-07-02
AT391137B (en) 1990-08-27
DK340387A (en) 1988-01-04
EP0251330A3 (en) 1989-06-28
NO872770D0 (en) 1987-07-02
KR880001675A (en) 1988-04-26
ZA874696B (en) 1988-01-04
MX7189A (en) 1993-08-01
MC1833A1 (en) 1988-06-03
AU603364B2 (en) 1990-11-15
CS395091A3 (en) 1992-12-16
ATA264587A (en) 1990-02-15
FI88392C (en) 1993-05-10
PT85246A (en) 1987-08-01
FI872951A7 (en) 1988-01-04
ZW12787A1 (en) 1988-02-03

Similar Documents

Publication Publication Date Title
ES2108727T3 (en) TRIAZOLOPYRIMIDINE DERIVATIVES WITH FUNGICIDE ACTIVITY.
ES2053609T3 (en) DERIVATIVES OF UREA LIPOXIGENASA INHIBITORS.
ES2062974T3 (en) CEPHALOSPORIN COMPOUNDS, PREPARATION PROCEDURES AND ANTIBACTERIAL AGENTS.
ES2067500T3 (en) 1-INDOLYLALKYL-4- (PIRIDINIL-SUBSTITUTED) PIPERAZINES.
FI980341A0 (en) 2-oxy-indole derivatives
ES474592A1 (en) PROCEDURE FOR THE PREPARATION OF IMIDAZOLI-NINA DERIVATIVES
ES2134755T3 (en) QUINOLINE DERIVATIVES AS LEUCOTRENE D4 ANTAGONISTS, COMPOSITIONS CONTAINING THE SAME, AND PROCEDURES FOR THEIR PREPARATION.
ES2052696T3 (en) FUNGICIDES.
YU157191A (en) RECEPTORA FIBRINOGENA ANTAGONISTS
ES2055860T3 (en) 2-AMINOPYRIMIDINONE DERIVATIVES.
ES2126097T3 (en) DERIVATIVES OF PHOSPHONIC DIESTERS.
FI911980A0 (en) N- (3-FLUOR-2-PHOSPHONYLMETHOXIPROPYL) DERIVATIVES OF THE HETEROCYCLIC PURIN- OCH PYRIMIDINE BASE, DERAS FRAMSTAELLNING OCH ANVAENDNING.
ES2174298T3 (en) DERIVATIVES OF AMINOTIAZOL, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2038678T3 (en) PROCEDURE FOR THE PREPARATION OF N- (2-ALQUIL-3-MERCAPTO-GLUTARIL) -ALFAMINO-ACIDOS.
ES2036213T3 (en) PROCEDURE FOR PREPARING TETRAHYDROISOKINOLIN-1-ILYCLE DERIVATIVES OF CARBOXYL ACIDS.
AR010195A1 (en) TRICICLIC BENZACEPINE VASOPRESSIN ANTAGONISTS AND PROCEDURE FOR THEIR PREPARATION.
ES2062706T3 (en) NEW DERIVATIVES OF AMINO-METHYL-PIPERIDINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
MX9300742A (en) QUINOLINE DERIVATIVES SUBSTITUTED WITH BIPHENYL AND PHARMACEUTICAL COMPOSITION CONTAINING THEM.
ES2039361T3 (en) DERIVATIVES OF 3-VINYL- AND 3-ETHINYL-BETA-CARBOLINS, THEIR PREPARATION AND THEIR USE AS MEDICINES.
ES2064729T3 (en) RUTHENIUM (III) COMPLEXES AS ANTINEOPLASTIC AGENTS.
ES2108595B1 (en) DERIVATIVES OF 3 (2H) -PIRIDACINONE AND PROCEDURE FOR ITS PREPARATION.
MX9301045A (en) PROCEDURE FOR PREPARING FIBRINOGEN RECEIVING ANTAGONISTS.
ES2032752T3 (en) PREPARATION PROCEDURE FOR 1-BENZENOSULFONYL-2-OXO-5-ALCOXY-PIRROLIDINE DERIVATIVES.
ES557783A0 (en) A PROCEDURE FOR THE PREPARATION OF B-LACTAMA DERIVATIVES
ES2117654T3 (en) CHOLECYSTOCININ ANTAGONISTS.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 251330

Country of ref document: ES